{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T03:16:58Z","timestamp":1792120618591,"version":"4.4.0"},"reference-count":140,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2023,5,15]],"date-time":"2023-05-15T00:00:00Z","timestamp":1684108800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Core Grant","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]},{"name":"Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>Chimeric Antigen Receptor T (CAR-T) cell therapy has dramatically changed prognosis and treatment of relapsed and refractory hematologic malignancies. Currently the 6 FDA approved products target various surface antigens. While CAR-T therapy achieves good response, life-threatening toxicities have been reported. Mechanistically, can be divided into two categories: (1) toxicities related to T-cell activation and release of high levels of cytokines: or (2) toxicities resulting from interaction between CAR and CAR targeted antigen expressed on non-malignant cells (i.e., on-target, off-tumor effects). Variations in conditioning therapies, co-stimulatory domains, CAR T-cell dose and anti-cytokine administration, pose a challenge in distinguishing cytokine mediated related toxicities from on-target, off-tumor toxicities. Timing, frequency, severity, as well as optimal management of CAR T-cell-related toxicities vary significantly between products and are likely to change as newer therapies become available. Currently the FDA approved CARs are targeted towards the B-cell malignancies however the future holds promise of expanding the target to solid tumor malignancies. Further highlighting the importance of early recognition and intervention for early and late onset CAR-T related toxicity. This contemporary review aims to describe presentation, grading and management of commonly encountered toxicities, short- and long-term complications, discuss preventive strategies and resource utilization.<\/jats:p>","DOI":"10.3390\/curroncol30050378","type":"journal-article","created":{"date-parts":[[2023,5,16]],"date-time":"2023-05-16T02:45:47Z","timestamp":1684205147000},"page":"5003-5023","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Management and Prevention of Cellular-Therapy-Related Toxicity: Early and Late Complications"],"prefix":"10.3390","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9623-9611","authenticated-orcid":false,"given":"Simon R.","family":"Mucha","sequence":"first","affiliation":[{"name":"Department of Critical Care Medicine, Respiratory Institute, Cleveland Clinic, Cleveland, OH 44195, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabalini","family":"Rajendram","sequence":"additional","affiliation":[{"name":"Critical Care Medicine, Department of Anesthesiology and Critical Care Medicine, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1016\/j.ymthe.2020.09.015","article-title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","volume":"28","author":"Wagner","year":"2020","journal-title":"Mol. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s42255-022-00537-5","article-title":"CAR-based therapies: Opportunities for immuno-medicine beyond cancer","volume":"4","author":"Aghajanian","year":"2022","journal-title":"Nat. Metab."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (CAR) T-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_6","first-page":"2307","article-title":"5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"3978","DOI":"10.1200\/JCO.21.01992","article-title":"Management of Immune-Related Adverse Events in Patients Treated with Chimeric Antigen Receptor T-Cell Therapy: ASCO Guideline","volume":"39","author":"Santomasso","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"322","DOI":"10.6004\/jnccn.2022.0021","article-title":"NCCN Guidelines\u00ae Insights: Hodgkin Lymphoma, Version 2.2022","volume":"20","author":"Hoppe","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1038\/nri3405","article-title":"Molecular mechanisms of T cell co-stimulation and co-inhibition","volume":"13","author":"Chen","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41571-021-00530-z","article-title":"A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains","volume":"18","author":"Cappell","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): A multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","article-title":"Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma","volume":"384","author":"Munshi","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1016\/S0140-6736(21)00933-8","article-title":"Ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T-cell therapy in patients with relapsed or refractory multiple myeloma (CARTITUDE-1): A phase 1b\/2 open-label study","volume":"398","author":"Berdeja","year":"2021","journal-title":"Lancet"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"581-e1","DOI":"10.1016\/j.jtct.2022.05.026","article-title":"Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States","volume":"28","author":"Jacobson","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.3324\/haematol.2022.280805","article-title":"Axicabtagene ciloleucel compared to tisagenlecleucel for the treatment of aggressive B-cell lymphoma","volume":"108","author":"Kwon","year":"2022","journal-title":"Haematologica"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"855730","DOI":"10.3389\/fimmu.2022.855730","article-title":"Best Treatment Option for Patients with Refractory Aggressive B-Cell Lymphoma in the CAR-T Cell Era: Real-World Evidence From GELTAMO\/GETH Spanish Groups","volume":"13","author":"Gutierrez","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/j.jtct.2022.07.011","article-title":"Patterns of Use, Outcomes, and Resource Utilization among Recipients of Commercial Axicabtagene Ciloleucel and Tisagenlecleucel for Relapsed\/Refractory Aggressive B Cell Lymphomas","volume":"28","author":"Riedell","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood.2021014497","article-title":"Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL","volume":"139","author":"Gauthier","year":"2022","journal-title":"Blood"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1111\/bjh.18209","article-title":"A national service for delivering CD19 CAR-T in large B-cell lymphoma\u2014The UK real-world experience","volume":"198","author":"Kuhnl","year":"2022","journal-title":"Br. J. Haematol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.1038\/s41591-022-01969-y","article-title":"A real-world comparison of tisagenlecleucel and axicabtagene ciloleucel CAR T cells in relapsed or refractory diffuse large B cell lymphoma","volume":"28","author":"Bachy","year":"2022","journal-title":"Nat. Med."},{"key":"ref_23","first-page":"349","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","volume":"140","author":"Bethge","year":"2022","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3214","DOI":"10.1002\/cam4.3881","article-title":"Real-world evidence of tisagenlecleucel for the treatment of relapsed or refractory large B-cell lymphoma","volume":"10","author":"Iacoboni","year":"2021","journal-title":"Cancer Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results from the US Lymphoma CAR T Consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"3606","DOI":"10.1182\/bloodadvances.2021006922","article-title":"Real-world evidence of brexucabtagene autoleucel for the treatment of relapsed or refractory mantle cell lymphoma","volume":"6","author":"Iacoboni","year":"2022","journal-title":"Blood Adv."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1200\/JCO.22.01365","article-title":"Idecabtagene Vicleucel for Relapsed\/Refractory Multiple Myeloma: Real-World Experience from the Myeloma CAR T Consortium","volume":"41","author":"Hansen","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1182\/blood-2019-124750","article-title":"Post-Marketing Use Outcomes of an Anti-CD19 Chimeric Antigen Receptor (CAR) T Cell Therapy, Axicabtagene Ciloleucel (Axi-Cel), for the Treatment of Large B Cell Lymphoma (LBCL) in the United States (US)","volume":"134","author":"Pasquini","year":"2019","journal-title":"Blood"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.jaip.2021.10.037","article-title":"Hypogammaglobulinemia After Chimeric Antigen Receptor (CAR) T-Cell Therapy: Characteristics, Management, and Future Directions","volume":"10","author":"Wat","year":"2021","journal-title":"J. Allergy Clin. Immunol. Pract."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.blre.2018.11.002","article-title":"Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management","volume":"34","author":"Brudno","year":"2019","journal-title":"Blood Rev."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T cell\u2013induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of Predictive Biomarkers for Cytokine Release Syndrome after Chimeric Antigen Receptor T-cell Therapy for Acute Lymphoblastic Leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after CD19 chimeric antigen receptor\u2013modified T-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2799","DOI":"10.1182\/bloodadvances.2021004575","article-title":"CRP and ferritin in addition to the EASIX score predict CAR-T\u2013related toxicity","volume":"5","author":"Greenbaum","year":"2021","journal-title":"Blood Adv."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"611366","DOI":"10.3389\/fimmu.2021.611366","article-title":"Characteristics and Risk Factors of Cytokine Release Syndrome in Chimeric Antigen Receptor T Cell Treatment","volume":"12","author":"Yan","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1634\/theoncologist.2018-0028","article-title":"FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome","volume":"23","author":"Le","year":"2018","journal-title":"Oncologist"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"387","DOI":"10.6004\/jnccn.2022.0020","article-title":"Management of Immunotherapy-Related Toxicities, Version 1.2022, NCCN Clinical Practice Guidelines in Oncology","volume":"20","author":"Thompson","year":"2022","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"e001511","DOI":"10.1136\/jitc-2020-001511","article-title":"Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events","volume":"8","author":"Maus","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1111\/bjh.17527","article-title":"Prophylactic corticosteroid use in patients receiving axicabtagene ciloleucel for large B-cell lymphoma","volume":"194","author":"Oluwole","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1038\/nrrheum.2015.179","article-title":"Macrophage activation syndrome in the era of biologic therapy","volume":"12","author":"Grom","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1182\/bloodadvances.2020001605","article-title":"Frequency and spectrum of disease-causing variants in 1892 patients with suspected genetic HLH disorders","volume":"4","author":"Dong","year":"2020","journal-title":"Blood Adv."},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"613","DOI":"10.3109\/10428194.2010.551153","article-title":"Malignancy-associated hemophagocytic lymphohistiocytosis in adults: A retrospective population-based analysis from a single center","volume":"52","author":"Machaczka","year":"2011","journal-title":"Leuk. Lymphoma"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1002\/cncr.30826","article-title":"A consensus review on malignancy-associated hemophagocytic lymphohistiocytosis in adults","volume":"123","author":"Daver","year":"2017","journal-title":"Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1080\/10428190701713630","article-title":"Clinical characteristics of T-cell lymphoma associated with hemophagocytic syndrome: Comparison of T-cell lymphoma with and without hemophagocytic syndrome","volume":"49","author":"Tong","year":"2008","journal-title":"Leuk. Lymphoma"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: Diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2006","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/art.38690","article-title":"Development and Validation of the HScore, a Score for the Diagnosis of Reactive Hemophagocytic Syndrome","volume":"66","author":"Fardet","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/10428194.2021.2024817","article-title":"Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed\/refractory diffuse large B-Cell lymphoma","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy\u2014Assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br. J. Haematol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"524","DOI":"10.3389\/fimmu.2020.00524","article-title":"Diagnosis and Management of Secondary HLH\/MAS Following HSCT and CAR-T Cell Therapy in Adults; A Review of the Literature and a Survey of Practice Within EBMT Centres on Behalf of the Autoimmune Diseases Working Party (ADWP) and Transplant Complications Working Party (TCWP)","volume":"11","author":"Sandler","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1002\/ajh.26668","article-title":"Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: Update from the FDA and Vizient databases","volume":"97","author":"Priyadarshini","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-Cell Selection Affects Chimeric Antigen Receptor (CAR) T-Cell Potency and Toxicity: Updated Results from a Phase I Anti-CD22 CAR T-Cell Trial","volume":"38","author":"Shah","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1182\/blood.2021011898","article-title":"Characterization of HLH-like manifestations as a CRS variant in patients receiving CD22 CAR T cells","volume":"138","author":"Lichtenstein","year":"2021","journal-title":"Blood"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1182\/blood.2019002289","article-title":"Emapalumab for the treatment of relapsed\/refractory hemophagocytic lymphohistiocytosis","volume":"134","author":"Vallurupalli","year":"2019","journal-title":"Blood"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J. Clin. Investig."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1093\/neuonc\/noaa183","article-title":"Immune effector cell\u2013associated neurotoxicity syndrome after chimeric antigen receptor T-cell therapy for lymphoma: Predictive biomarkers and clinical outcomes","volume":"23","author":"Holtzman","year":"2020","journal-title":"Neuro-Oncology"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and Biological Correlates of Neurotoxicity Associated with CAR T-cell Therapy in Patients with B-cell Acute Lymphoblastic Leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial Activation and Blood\u2013Brain Barrier Disruption in Neurotoxicity after Adoptive Immunotherapy with CD19 CAR-T Cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"1110647","DOI":"10.3389\/fneur.2023.1110647","article-title":"A systematic framework for predictive biomarkers in immune effector cell-associated neurotoxicity syndrome","volume":"14","author":"Butt","year":"2023","journal-title":"Front. Neurol."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s42466-021-00166-5","article-title":"Neurological management and work-up of neurotoxicity associated with CAR T cell therapy","volume":"4","author":"Bonda","year":"2022","journal-title":"Neurol. Res. Pract."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1002\/ana.25315","article-title":"Neurotoxicity after CTL019 in a pediatric and young adult cohort","volume":"84","author":"Gofshteyn","year":"2018","journal-title":"Ann. Neurol."},{"key":"ref_70","doi-asserted-by":"crossref","unstructured":"Santomasso, B.D., Gust, J., and Perna, F. (2023). How I treat unique and difficult to manage cases of CAR T-cell therapy associated neurotoxicity. Blood.","DOI":"10.1182\/blood.2022017604"},{"key":"ref_71","first-page":"E50","article-title":"Chimeric Antigen Receptor T-Cell Neurotoxicity Neuroimaging: More Than Meets the Eye","volume":"40","author":"Gust","year":"2019","journal-title":"Am. J. Neuroradiol."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann. Neurol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3943","DOI":"10.1182\/bloodadvances.2020002228","article-title":"Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically Ill Patients Treated for Chimeric Antigen Receptor-Related Toxicity: A Multicenter Study*","volume":"50","author":"Gutierrez","year":"2021","journal-title":"Crit. Care Med."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41408-022-00657-x","article-title":"Acute seizures and status epilepticus in immune effector cell associated neurotoxicity syndrome (ICANS)","volume":"12","author":"Saw","year":"2022","journal-title":"Blood Cancer J."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1182\/bloodadvances.2020001626","article-title":"Intrathecal chemotherapy for management of steroid-refractory CAR T-cell\u2013associated neurotoxicity syndrome","volume":"4","author":"Shah","year":"2020","journal-title":"Blood Adv."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3853","DOI":"10.21873\/anticanres.15876","article-title":"Intrathecal Chemotherapy as a Potential Treatment for Steroid-refractory Immune Effector Cell-associated Neurotoxicity Syndrome","volume":"42","author":"Asawa","year":"2022","journal-title":"Anticancer. Res."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/s41571-022-00607-3","article-title":"Preparing for CAR T cell therapy: Patient selection, bridging therapies and lymphodepletion","volume":"19","author":"Amini","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1002\/ajh.26301","article-title":"Efficacy and safety of CD19-directed CAR-T cell therapies in patients with relapsed\/refractory aggressive B-cell lymphomas: Observations from the JULIET, ZUMA -1, and TRANSCEND trials","volume":"96","author":"Westin","year":"2021","journal-title":"Am. J. Hematol."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1080\/10428194.2021.2010069","article-title":"Comparative efficacy of tisagenlecleucel and lisocabtagene maraleucel among adults with relapsed\/refractory large B-cell lymphomas: An indirect treatment comparison","volume":"63","author":"Schuster","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s40164-022-00268-z","article-title":"Matching-adjusted indirect treatment comparison of chimeric antigen receptor T-cell therapies for third-line or later treatment of relapsed or refractory large B-cell lymphoma: Lisocabtagene maraleucel versus tisagenlecleucel","volume":"11","author":"Cartron","year":"2022","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13045-021-01144-9","article-title":"Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma","volume":"14","author":"Maloney","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_84","doi-asserted-by":"crossref","unstructured":"Oluwole, O.O., Chen, J.M., Chan, K., Patel, A.R., Jansen, J.P., Keeping, S., Zheng, Y., Snider, J.T., and Locke, F.L. (2022). Matching-adjusted indirect comparison of axi-cel and liso-cel in relapsed or refractory large B-cell lymphoma. Leuk. Lymphoma, 1\u201311.","DOI":"10.1080\/10428194.2022.2113526"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1038\/s41571-022-00711-4","article-title":"Clash of the titans: Axi-cel versus tisa-cel for advanced-stage DLBCL","volume":"20","author":"Maziarz","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"3673","DOI":"10.1182\/blood.2022016676","article-title":"CAR T-cell therapy: Which product for which patient?","volume":"139","author":"Strati","year":"2022","journal-title":"Blood"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"2099","DOI":"10.1038\/s41591-021-01564-7","article-title":"Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy","volume":"27","author":"Aleman","year":"2021","journal-title":"Nat. Med."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): A single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.bbmt.2019.08.003","article-title":"Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells","volume":"26","author":"Cordeiro","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"3805","DOI":"10.1200\/JCO.20.01467","article-title":"Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy","volume":"38","author":"Cappell","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.jtct.2020.10.002","article-title":"Late Effects after Chimeric Antigen Receptor T Cell Therapy for Lymphoid Malignancies","volume":"27","author":"Chakraborty","year":"2020","journal-title":"Transplant. Cell. Ther."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1038\/s41409-022-01756-w","article-title":"Infectious complications, immune reconstitution, and infection prophylaxis after CD19 chimeric antigen receptor T-cell therapy","volume":"57","author":"Wudhikarn","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41408-020-00346-7","article-title":"Infection during the first year in patients treated with CD19 CAR T cells for diffuse large B cell lymphoma","volume":"10","author":"Wudhikarn","year":"2020","journal-title":"Blood Cancer J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1182\/blood-2017-07-793760","article-title":"Infectious complications of CD19-targeted chimeric antigen receptor\u2013modified T-cell immunotherapy","volume":"131","author":"Hill","year":"2018","journal-title":"Blood"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1016\/j.jaci.2022.01.025","article-title":"Practical guidance for the diagnosis and management of secondary hypogammaglobulinemia: A Work Group Report of the AAAAI Primary Immunodeficiency and Altered Immune Response Committees","volume":"149","author":"Otani","year":"2022","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_99","first-page":"215","article-title":"Recommendations for screening, monitoring, prevention, and prophylaxis of infections in adult and pediatric patients receiving CAR T-cell therapy: A position paper","volume":"49","author":"Iacoboni","year":"2020","journal-title":"Infection"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"3776","DOI":"10.1182\/bloodadvances.2020002509","article-title":"Hematopoietic recovery in patients receiving chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"4","author":"Jain","year":"2020","journal-title":"Blood Adv."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1038\/s41409-019-0487-3","article-title":"Early and late hematologic toxicity following CD19 CAR-T cells","volume":"54","author":"Fried","year":"2019","journal-title":"Bone Marrow Transplant."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"978","DOI":"10.3324\/haematol.2019.238634","article-title":"Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma","volume":"106","author":"Logue","year":"2020","journal-title":"Haematologica"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1182\/bloodadvances.2020004142","article-title":"Severe cytokine release syndrome is associated with hematologic toxicity following CD19 CAR T-cell therapy","volume":"6","author":"Juluri","year":"2022","journal-title":"Blood Adv."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1182\/blood.2020006216","article-title":"Tocilizumab not associated with increased infection risk after CAR T-cell therapy: Implications for COVID-19?","volume":"136","author":"Frigault","year":"2020","journal-title":"Blood"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1182\/bloodadvances.2020002732","article-title":"Immune reconstitution and infectious complications following axicabtagene ciloleucel therapy for large B-cell lymphoma","volume":"5","author":"Baird","year":"2021","journal-title":"Blood Adv."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"2256","DOI":"10.1056\/NEJMra1404711","article-title":"Renal Complications of Hematopoietic-Cell Transplantation","volume":"374","author":"Hingorani","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"2378","DOI":"10.1111\/j.1600-6143.2008.02408.x","article-title":"Chronic Kidney Disease After Hematopoietic Cell Transplantation: A Systematic Review","volume":"8","author":"Ellis","year":"2008","journal-title":"Am. J. Transplant."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1053\/j.ajkd.2019.10.011","article-title":"Acute Kidney Injury and Electrolyte Abnormalities After Chimeric Antigen Receptor T-Cell (CAR-T) Therapy for Diffuse Large B-Cell Lymphoma","volume":"76","author":"Gupta","year":"2020","journal-title":"Am. J. Kidney Dis."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1016\/j.bbmt.2020.02.012","article-title":"Acute Kidney Injury after CAR-T Cell Therapy: Low Incidence and Rapid Recovery","volume":"26","author":"Gutgarts","year":"2020","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Ansari, R., Caimi, P., Lee, H.J., Chen, Z., and Rashidi, A. (2022). Renal outcomes after chimeric antigen receptor T-cell therapy: A single-center perspective. Nephrol. Dial. Transplant.","DOI":"10.1093\/ndt\/gfac048"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1038\/s41409-022-01767-7","article-title":"Comparison of short- and long-term adverse kidney outcomes after chimeric antigen receptor T cell therapy and autologous hematopoietic stem cell transplant for diffuse large B cell lymphoma","volume":"57","author":"Hanna","year":"2022","journal-title":"Bone Marrow Transplant."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/j.jacc.2019.10.038","article-title":"Cardiovascular Events Among Adults Treated With Chimeric Antigen Receptor T-Cells (CAR-T)","volume":"74","author":"Alvi","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"3109","DOI":"10.1016\/j.jacc.2019.10.028","article-title":"Chimeric Antigen Receptor T-Cells and Cardiovascular Toxicity","volume":"74","author":"Lancellotti","year":"2019","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.bbmt.2019.09.037","article-title":"Patient-Reported Neuropsychiatric Outcomes of Long-Term Survivors after Chimeric Antigen Receptor T Cell Therapy","volume":"26","author":"Ruark","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e355","DOI":"10.1016\/S2352-3026(21)00060-0","article-title":"Outcomes in patients treated with chimeric antigen receptor T-cell therapy who were admitted to intensive care (CARTTAS): An international, multicentre, observational cohort study","volume":"8","author":"Azoulay","year":"2021","journal-title":"Lancet Haematol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1080\/13696998.2020.1769109","article-title":"Estimation of total costs in patients with relapsed or refractory diffuse large B-cell lymphoma receiving tisagenlecleucel from a US hospital\u2019s perspective","volume":"23","author":"Yang","year":"2020","journal-title":"J. Med. Econ."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1007\/s00277-022-04881-0","article-title":"Resource utilization for chimeric antigen receptor T cell therapy versus autologous hematopoietic cell transplantation in patients with B cell lymphoma","volume":"101","author":"Ring","year":"2022","journal-title":"Ann. Hematol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1164\/rccm.202002-0286LE","article-title":"ICU Resource Use in Critically III Patients following Chimeric Antigen Receptor T-Cell Therapy","volume":"202","author":"Brown","year":"2020","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2169","DOI":"10.1080\/10428194.2021.1910686","article-title":"Postinfusion monitoring costs by site of care for patients with relapsed\/refractory large B-cell lymphoma receiving third- or later-line treatment with lisocabtagene maraleucel in the TRANSCEND NHL 001 and OUTREACH trials","volume":"62","author":"Palomba","year":"2021","journal-title":"Leuk. Lymphoma"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"404-e1","DOI":"10.1016\/j.jtct.2022.03.021","article-title":"Health Care Resource Utilization and Total Costs of Care Among Patients with Diffuse Large B Cell Lymphoma Treated with Chimeric Antigen Receptor T Cell Therapy in the United States","volume":"28","author":"Keating","year":"2022","journal-title":"Transplant. Cell. Ther."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1182\/bloodadvances.2020003531","article-title":"Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel\u2013treated patients in the TRANSCEND NHL 001 trial","volume":"5","author":"Abramson","year":"2021","journal-title":"Blood Adv."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1080\/10428194.2022.2060503","article-title":"Real-world healthcare resource utilization and costs associated with tisagenlecleucel and axicabtagene ciloleucel among patients with diffuse large B-cell lymphoma: An analysis of hospital data in the United States","volume":"63","author":"Maziarz","year":"2022","journal-title":"Leuk. Lymphoma"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"e002056","DOI":"10.1136\/jitc-2020-002056","article-title":"Perspectives on outpatient administration of CAR-T cell therapy in aggressive B-cell lymphoma and acute lymphoblastic leukemia","volume":"9","author":"Myers","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/s41591-021-01245-5","article-title":"Homozygous BCMA gene deletion in response to anti-BCMA CAR T cells in a patient with multiple myeloma","volume":"27","author":"Dietrich","year":"2021","journal-title":"Nat. Med."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1158\/2159-8290.CD-18-0442","article-title":"Tumor Antigen Escape from CAR T-cell Therapy","volume":"8","author":"Majzner","year":"2018","journal-title":"Cancer Discov."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Cappell, K.M., and Kochenderfer, J.N. (2023). Long-term outcomes following CAR T cell therapy: What we know so far. Nat. Rev. Clin. Oncol., 1\u201313.","DOI":"10.1038\/s41571-023-00754-1"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1182\/blood.2021010930","article-title":"CD19 target evasion as a mechanism of relapse in large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"138","author":"Plaks","year":"2021","journal-title":"Blood"},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1002\/ajh.26718","article-title":"Long-term outcomes and predictors of early response, late relapse, and survival for patients treated with bispecific LV20.19 CAR T-cells","volume":"97","author":"Zurko","year":"2022","journal-title":"Am. J. Hematol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"876339","DOI":"10.3389\/fimmu.2022.876339","article-title":"Impact of Manufacturing Procedures on CAR T Cell Functionality","volume":"13","author":"Watanabe","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1172\/JCI125423","article-title":"CD19 CAR T cell product and disease attributes predict leukemia remission durability","volume":"129","author":"Finney","year":"2019","journal-title":"J. Clin. Investig."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1182\/blood.V128.22.218.218","article-title":"Long-Term Outcomes Following CD19 CAR T Cell Therapy for B-ALL Are Superior in Patients Receiving a Fludarabine\/Cyclophosphamide Preparative Regimen and Post-CAR Hematopoietic Stem Cell Transplantation","volume":"128","author":"Lee","year":"2016","journal-title":"Blood"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1182\/blood-2018-11-883710","article-title":"Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy","volume":"133","author":"Hay","year":"2019","journal-title":"Blood"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor\u2013positive T cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1200\/JCO.2014.58.0225","article-title":"Human Epidermal Growth Factor Receptor 2 (HER2) \u2013Specific Chimeric Antigen Receptor\u2013Modified T Cells for the Immunotherapy of HER2-Positive Sarcoma","volume":"33","author":"Ahmed","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.1158\/2159-8290.CD-21-0407","article-title":"A Phase I Trial of Regional Mesothelin-Targeted CAR T-cell Therapy in Patients with Malignant Pleural Disease, in Combination with the Anti\u2013PD-1 Agent Pembrolizumab","volume":"11","author":"Adusumilli","year":"2021","journal-title":"Cancer Discov."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced with a Chimeric Antigen Receptor Recognizing ERBB2","volume":"18","author":"Yang","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1158\/2326-6066.CIR-17-0211","article-title":"High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model","volume":"6","author":"Richman","year":"2018","journal-title":"Cancer Immunol. Res."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13046-022-02327-z","article-title":"CAR race to cancer immunotherapy: From CAR T, CAR NK to CAR macrophage therapy","volume":"41","author":"Pan","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: Design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/378\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:35:13Z","timestamp":1760124913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/30\/5\/378"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,15]]},"references-count":140,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2023,5]]}},"alternative-id":["curroncol30050378"],"URL":"https:\/\/doi.org\/10.3390\/curroncol30050378","relation":{},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,15]]}}}